iSpecimen Expands Management Team With Doug Williams As Chief Technology Officer

LEXINGTON, Mass., June 1, 2015 /PRNewswire/ -- iSpecimen, a trusted source of customized human biospecimen collections, is pleased to announce the appointment of Doug Williams to the position of Chief Technology Officer (CTO). Williams will be responsible for leading the team that builds out iSpecimen's state-of-the-art, cloud-based platform that matches biomedical researchers with high quality, richly-annotated human biospecimens that would otherwise be discarded by hospitals and labs after clinical testing is complete. With more than 25 years of technology product development experience, Williams brings deep expertise in building market-leading solutions to iSpecimen. Founded in 2009, the company recently released the latest iteration of its technology and continues to grow its prestigious supplier network and researcher customer base.

"We are thrilled to welcome Doug to the iSpecimen team as we continue ramping up our commercialization efforts and scaling our operations," said Christopher Ianelli, MD, PhD, Chief Executive Officer of iSpecimen. "Technology is critical to linking millions of patient biospecimens to the many researchers who need them. Doug will help us continue driving innovation that makes it easier for hospitals, labs, and biobanks to forward biomaterial to the hands of people developing tomorrow's medical breakthroughs."

Prior to joining iSpecimen, Williams was involved with several highly successful Boston-area companies that today are globally-recognized as technology innovators. Most recently, Williams was at FitnessKeeper, where as Vice President of Engineering he was responsible for the company's ability to scale to more than 40 million users and triple consumer engagement for RunKeeper, which Time Magazine called one of the 50 best apps. Previously, he was Vice President of Engineering and Information Technology at Zipcar, as it grew to become the world's leading car-sharing company.

"I'm excited to join iSpecimen to help scale our innovative healthcare technology platform to accelerate the medical research process," shared Doug Williams.  "By aggregating labs, biorepositories, and other organizations with access to patient specimens into one pool from which to pull, the technology consolidates, sorts, and procures a wealth of specimens and data for the myriad organizations that need them, serving as a one-stop source for biotech, pharma, and academic institutions."

About iSpecimen
Privately held and headquartered in Lexington, Mass., iSpecimen is a trusted, one-stop source of customized human biospecimen collections. Compliantly sourced from our diverse partner network of hospitals, labs, and other healthcare organizations, our solid and liquid biospecimens are delivered directly into the hands of biomedical researchers using unique, turnkey technology. Scientists gain access to a ready supply of the high-quality, richly-annotated human biospecimens they need from the patients they want. Supply partners gain an opportunity to further contribute to biomedical discovery, as well their bottom line. Ultimately, healthcare advances for all. For more information about iSpecimen, please visit

To view the original version on PR Newswire, visit:

SOURCE iSpecimen

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.